Although NRF2 activators are currently being explored as potential therapeutic agents for a variety of diseases [194,195], to date, only one clinical trial of the NRF2 activator sulforaphane has been registered for the treatment of patients with prodromal-to-mild AD (NCT04213391). This evidence concerns the gene NFE2L2 and Alzheimer disease.